estradiol 17 beta-cypionate

Trial	Outcome
NCT00059228 (2) [back to overview]	Beck Depression Inventory
NCT00059228 (2) [back to overview]	Beck Depression Inventory
NCT00293059 (54) [back to overview]	Change From Baseline in Blood Loss Volume for Participants With Excessive Bleeding to the Reference Period of 90 Days Under Treatment
NCT00293059 (54) [back to overview]	Menstrual Blood Loss Volume for Participants With Excessive Bleeding at Cycle 1
NCT00293059 (54) [back to overview]	Menstrual Blood Loss Volume for Participants With Excessive Bleeding at Cycle 3
NCT00293059 (54) [back to overview]	Menstrual Blood Loss Volume for Participants With Excessive Bleeding at Cycle 7
NCT00293059 (54) [back to overview]	Proportion of Participants Cured From Excessive Bleeding
NCT00293059 (54) [back to overview]	Proportion of Participants Cured From Frequent Bleeding
NCT00293059 (54) [back to overview]	Proportion of Participants Cured From Prolonged Bleeding
NCT00293059 (54) [back to overview]	Proportion of Participants With Improvement in the Investigator's Global Assessment Scale at Treatment Day 196
NCT00293059 (54) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire (Unscheduled Visit to Physician) at Treatment Day 84
NCT00293059 (54) [back to overview]	Proportion of Participants With Successful Treatment
NCT00293059 (54) [back to overview]	Change From Baseline in Blood Loss Volume for All Participants to the Reference Period of 90 Days Under Treatment
NCT00293059 (54) [back to overview]	Proportion of Participants With Improvement in the Participant's Overall Assessment Scale at Treatment Day 196
NCT00293059 (54) [back to overview]	Change From Baseline in EuroQoL (Quality of Life) 5 Dimensional Health Questionnaire (EQ-5D) Scores at Treatment Day 196
NCT00293059 (54) [back to overview]	Change From Baseline in EuroQoL (Quality of Life) 5 Dimensional Health Questionnaire (EQ-5D) Scores at Treatment Day 84
NCT00293059 (54) [back to overview]	Change From Baseline in Hematocrit (Hct) Concentrations at Treatment Day 196
NCT00293059 (54) [back to overview]	Change From Baseline in Hemoglobin Concentration at Treatment Day 196
NCT00293059 (54) [back to overview]	Proportion of Participants With Improvement in the Investigator's Global Assessment Scale at Treatment Day 84
NCT00293059 (54) [back to overview]	Change From Baseline in Hemoglobin Concentration at Treatment Day 84
NCT00293059 (54) [back to overview]	Change From Baseline in McCoy Female Sexuality Questionnaire (MFSQ) Scores at Treatment Day 196
NCT00293059 (54) [back to overview]	Change From Baseline in McCoy Female Sexuality Questionnaire (MFSQ) Scores at Treatment Day 84
NCT00293059 (54) [back to overview]	Change From Baseline in Number of Bleeding Days to the Reference Period of 90 Days Under Treatment
NCT00293059 (54) [back to overview]	Change From Baseline in Number of Bleeding Episodes to the Reference Period of 90 Days Under Treatment
NCT00293059 (54) [back to overview]	Change From Baseline in Number of Sanitary Protection Used at 90 Days of Treatment
NCT00293059 (54) [back to overview]	Change From Baseline in Psychological General Well-Being Index (PGWBI) Scores at Treatment Day 196
NCT00293059 (54) [back to overview]	Change From Baseline in Psychological General Well-Being Index (PGWBI) Scores at Treatment Day 84
NCT00293059 (54) [back to overview]	Change From Baseline in Serum Ferritin Concentration at Treatment Day 196
NCT00293059 (54) [back to overview]	Change From Baseline in Serum Ferritin Concentration at Treatment Day 84
NCT00293059 (54) [back to overview]	Change From Baseline in Visual Analogue Scale (VAS) of the EQ-5D Score at Treatment Day 196
NCT00293059 (54) [back to overview]	Change From Baseline in Visual Analogue Scale (VAS) of the EQ-5D Score at Treatment Day 84
NCT00293059 (54) [back to overview]	Change in Absolute Value From Baseline MBL to end-of Study MBL
NCT00293059 (54) [back to overview]	Menstrual Blood Loss Volume for All Participants at Cycle 1
NCT00293059 (54) [back to overview]	Menstrual Blood Loss Volume for All Participants at Cycle 3
NCT00293059 (54) [back to overview]	Menstrual Blood Loss Volume for All Participants at Cycle 7
NCT00293059 (54) [back to overview]	Proportion of Participants With Improvement in the Participant's Overall Assessment Scale at Treatment Day 84
NCT00293059 (54) [back to overview]	Proportion of Participants With no Dysfunctional Uterine Bleeding (DUB) Symptoms
NCT00293059 (54) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire (Additional Unscheduled Procedures) at Treatment Day 196
NCT00293059 (54) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire (Additional Unscheduled Procedures) at Treatment Day 84
NCT00293059 (54) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire (Any Medical Treatment) at Treatment Day 196
NCT00293059 (54) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire (Any Medical Treatment) at Treatment Day 84
NCT00293059 (54) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire (Change in the Employment Status) at Treatment Day 196
NCT00293059 (54) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire (Change in the Employment Status) at Treatment Day 84
NCT00293059 (54) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire (Days Missed From Work) at Treatment Day 196
NCT00293059 (54) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire (Days Missed From Work) at Treatment Day 84
NCT00293059 (54) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire (Out-of-pocket Expenses) at Treatment Day 196
NCT00293059 (54) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire (Out-of-pocket Expenses) at Treatment Day 84
NCT00293059 (54) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire (Productivity While Working) at Treatment Day 196
NCT00293059 (54) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire (Productivity While Working) at Treatment Day 84
NCT00293059 (54) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire (Received Ambulatory Services) at Treatment Day 196
NCT00293059 (54) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire (Received Ambulatory Services) at Treatment Day 84
NCT00293059 (54) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire (Regular Daily Activities) at Treatment Day 196
NCT00293059 (54) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire (Regular Daily Activities) at Treatment Day 84
NCT00293059 (54) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire (Unscheduled Outpatient Visit at Hospital) at Treatment Day 196
NCT00293059 (54) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire (Unscheduled Outpatient Visit at Hospital) at Treatment Day 84
NCT00293059 (54) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire (Unscheduled Visit to Physician) at Treatment Day 196
NCT00302731 (4) [back to overview]	Change in Total Cholesterol
NCT00302731 (4) [back to overview]	Endometrial Measurement
NCT00302731 (4) [back to overview]	Number of Participants Without Change in Baseline and Follow up Bone Density
NCT00302731 (4) [back to overview]	Number of Participants Without Change in Baseline and Follow up Mammograms
NCT00307801 (53) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire （no Out-of-pocket Expenses） at Treatment Day 196
NCT00307801 (53) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire （no Out-of-pocket Expenses） at Treatment Day 84
NCT00307801 (53) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire （Not Have Any Medical Treatment） at Treatment Day 196
NCT00307801 (53) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire （Not Have Any Medical Treatment） at Treatment Day 84
NCT00307801 (53) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire （Productivity While Working） at Treatment Day 196.
NCT00307801 (53) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire （Productivity While Working） at Treatment Day 84.
NCT00307801 (53) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire （Received Ambulatory Services） at Treatment Day 196
NCT00307801 (53) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire （Received Ambulatory Services） at Treatment Day 84
NCT00307801 (53) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire （Regular Daily Activities） at Treatment Day 196.
NCT00307801 (53) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire （Regular Daily Activities） at Treatment Day 84
NCT00307801 (53) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire （Unscheduled Outpatient Visit at Hospital） at Treatment Day 196
NCT00307801 (53) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire （Unscheduled Outpatient Visit at Hospital） at Treatment Day 84
NCT00307801 (53) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire （Unscheduled Outpatient Visit to Physician） at Treatment Day 196
NCT00307801 (53) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire （Unscheduled Outpatient Visit to Physician） at Treatment Day 84
NCT00307801 (53) [back to overview]	Proportion of Participants With Successful Treatment
NCT00307801 (53) [back to overview]	Proportion of Participants With Improvement in the Patient's Overall Assessment Scale at Treatment Day 196
NCT00307801 (53) [back to overview]	Change From Baseline in Number of Bleeding Episodes to the Reference Period of 90 Days Under Treatment
NCT00307801 (53) [back to overview]	Change From Baseline in Number of Sanitary Protection Used at 90 Days of Treatment
NCT00307801 (53) [back to overview]	Change From Baseline in Psychological General Well-Being Index (PGWBI) Score at Treatment Day 196.
NCT00307801 (53) [back to overview]	Change From Baseline in Psychological General Well-Being Index (PGWBI) Score at Treatment Day 84.
NCT00307801 (53) [back to overview]	Change From Baseline in Visual Analogue Scale (VAS) of the EQ-5D Score at Treatment Day 196.
NCT00307801 (53) [back to overview]	Change From Baseline in Visual Analogue Scale (VAS) of the EQ-5D Score at Treatment Day 84.
NCT00307801 (53) [back to overview]	Change in Absolute Value From Baseline Menstrual Blood Loss (MBL) to end-of Study MBL
NCT00307801 (53) [back to overview]	Menstrual Blood Loss Volume for All Participants at Cycle 1
NCT00307801 (53) [back to overview]	Menstrual Blood Loss Volume for All Participants at Cycle 3
NCT00307801 (53) [back to overview]	Menstrual Blood Loss Volume for All Participants at Cycle 7
NCT00307801 (53) [back to overview]	Menstrual Blood Loss Volume for Participants With Excessive Bleeding at Cycle 1.
NCT00307801 (53) [back to overview]	Menstrual Blood Loss Volume for Participants With Excessive Bleeding at Cycle 3.
NCT00307801 (53) [back to overview]	Menstrual Blood Loss Volume for Participants With Excessive Bleeding at Cycle 7.
NCT00307801 (53) [back to overview]	Proportion of Participants Cured From Excessive Bleeding
NCT00307801 (53) [back to overview]	Change From Baseline in Number of Bleeding Days to the Reference Period of 90 Days Under Treatment
NCT00307801 (53) [back to overview]	Change From Baseline in McCoy Female Sexuality Questionnaire (MFSQ) Score at Treatment Day 84
NCT00307801 (53) [back to overview]	Change From Baseline in McCoy Female Sexuality Questionnaire (MFSQ) Score at Treatment Day 196
NCT00307801 (53) [back to overview]	Change From Baseline in Hemoglobin Concentration at Treatment Day 84
NCT00307801 (53) [back to overview]	Change From Baseline in Hemoglobin Concentration at Treatment Day 196
NCT00307801 (53) [back to overview]	Change From Baseline in Hematocrit at Treatment Day 196.
NCT00307801 (53) [back to overview]	Change From Baseline in Ferritin Concentration at Treatment Day 84
NCT00307801 (53) [back to overview]	Change From Baseline in Ferritin Concentration at Treatment Day 196
NCT00307801 (53) [back to overview]	Change From Baseline in EuroQol 5 Dimensional (EQ-5D) Score at Treatment Day 84
NCT00307801 (53) [back to overview]	Change From Baseline in Blood Loss Volume for All Participants to the Reference Period of 90 Days Under Treatment
NCT00307801 (53) [back to overview]	Proportion of Participants Cured From Prolonged Bleeding
NCT00307801 (53) [back to overview]	Proportion of Participants With Improvement in the Investigator's Global Assessment Scale at Treatment Day 196
NCT00307801 (53) [back to overview]	Proportion of Participants With Improvement in the Investigator's Global Assessment Scale at Treatment Day 84
NCT00307801 (53) [back to overview]	Proportion of Participants With Improvement in the Patient's Overall Assessment Scale at Treatment Day 84
NCT00307801 (53) [back to overview]	Proportion of Participants With no Dysfunctional Uterine Bleeding (DUB) Symptoms
NCT00307801 (53) [back to overview]	Change From Baseline in EuroQol 5 Dimensional (EQ-5D) Score at Treatment Day 196
NCT00307801 (53) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire （Additional Unscheduled Procedures） at Treatment Day 196
NCT00307801 (53) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire （Additional Unscheduled Procedures） at Treatment Day 84
NCT00307801 (53) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire （Change in the Employment Status） at Treatment Day 196.
NCT00307801 (53) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire （Change in the Employment Status） at Treatment Day 84.
NCT00307801 (53) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire （Days Missed From Work） at Treatment Day 196
NCT00307801 (53) [back to overview]	Resource Use Assessment by Use of a Self Administered Questionnaire （Days Missed From Work） at Treatment Day 84
NCT00307801 (53) [back to overview]	Change From Baseline in Blood Loss Volume for Participants With Excessive Bleeding to the Reference Period of 90 Days Under Treatment.
NCT00357006 (1) [back to overview]	Positive and Negative Syndrome Scale (PANSS)
NCT00387829 (2) [back to overview]	Radiological, Pain, and Functional Outcome Assessments
NCT00387829 (2) [back to overview]	Radiological, Pain, and Functional Outcome Assessments
NCT00394771 (12) [back to overview]	Days With Bleeding During Active Cycle 1 (Day 1-84)
NCT00394771 (12) [back to overview]	Participants With Bleeding and/or Spotting Days During the 7-day Withdrawal During Cycle 1 (Day 85-91)
NCT00394771 (12) [back to overview]	Days With Bleeding and/or Spotting During Active Cycle 1 (Day 1-84)
NCT00394771 (12) [back to overview]	Participants Reporting Hormone-Related Symptoms During Active Cycle 1 (Day 1-84)
NCT00394771 (12) [back to overview]	Days With Bleeding and/or Spotting During Active Cycle 2 (Day 92-176)
NCT00394771 (12) [back to overview]	Participants With Bleeding and/or Spotting Days During the 7-day Withdrawal During Cycle 2 (Day 177-183)
NCT00394771 (12) [back to overview]	Participants Reporting Hormone-Related Symptoms During the 7-day Withdrawal Cycle 2 (Day 177-183)
NCT00394771 (12) [back to overview]	Participants Reporting Hormone-Related Symptoms During the 7-day Withdrawal Cycle 1 (Day 85-91)
NCT00394771 (12) [back to overview]	Participants Reporting Hormone-Related Symptoms During Active Cycle 2 (Day 92-176)
NCT00394771 (12) [back to overview]	Number of Moderate to Heavy Bleeding Days During Active Cycle 2 (Day 92-176)
NCT00394771 (12) [back to overview]	Number of Moderate to Heavy Bleeding Days During Active Cycle 1 (Day 1-84)
NCT00394771 (12) [back to overview]	Days With Bleeding During Active Cycle 2 (Day 92-176)
NCT00420342 (12) [back to overview]	Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 112 mmHg (Posthoc Analysis)
NCT00420342 (12) [back to overview]	Change From Baseline to Week 8 in Mean 24-hour SBP From the Ambulatory Blood Pressure Monitoring (ABPM) Measurements in Full Analysis Set (FAS) Population
NCT00420342 (12) [back to overview]	Change From Baseline to Week 8 in Mean 24-hour SBP From the ABPM Measurements in Per Protocol Population
NCT00420342 (12) [back to overview]	Change From Baseline to Week 8 in Mean 24-hour DBP From the ABPM Measurements
NCT00420342 (12) [back to overview]	Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 120 mmHg (Posthoc Analysis)
NCT00420342 (12) [back to overview]	Number of Subjects Who Are Sodium Sensitive at Baseline and Week 8
NCT00420342 (12) [back to overview]	Change From Baseline to Week 8 in Office Cuff SBP and DBP at Trough
NCT00420342 (12) [back to overview]	Change From Baseline to Week 8 in Mean Day Time, Mean Nighttime and Mean Trough SBP From the ABPM Measurements
NCT00420342 (12) [back to overview]	Change From Baseline to Week 8 in Mean Day Time, Mean Nighttime and Mean Trough DBP From the ABPM Measurements
NCT00420342 (12) [back to overview]	Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 130 mmHg (Posthoc Analysis)
NCT00420342 (12) [back to overview]	Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 124 mmHg (Posthoc Analysis)
NCT00420342 (12) [back to overview]	Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean > 116 mmHg (Posthoc Analysis)
NCT00544882 (9) [back to overview]	Number of Days of Bleeding During Unscheduled and Scheduled Study Periods
NCT00544882 (9) [back to overview]	Change From Cycle 2 Days 1 - 20 to Cycle 2 Days 21 - 28 in Maximum Follicle Size
NCT00544882 (9) [back to overview]	Serum Inhibin-B Levels by Cycle Day
NCT00544882 (9) [back to overview]	Serum Follicle Stimulating Hormone (FSH) Levels by Cycle Day
NCT00544882 (9) [back to overview]	Serum Estradiol Levels by Cycle Day
NCT00544882 (9) [back to overview]	Percentage of Participants With Bleeding or Spotting During Unscheduled and Scheduled Study Periods
NCT00544882 (9) [back to overview]	Percentage of Participants With Bleeding During Unscheduled and Scheduled Study Periods
NCT00544882 (9) [back to overview]	Percentage of Follicles Greater Than 5 mm in Diameter
NCT00544882 (9) [back to overview]	Number of Days of Bleeding or Spotting During Unscheduled and Scheduled Study Periods
NCT00612508 (2) [back to overview]	Thickness of the Vaginal Epithelium (in mm)With Means and Standard Deviations Reported.
NCT00612508 (2) [back to overview]	Adverse Events
NCT00698035 (7) [back to overview]	Change in Vaginal Epithelium Scores
NCT00698035 (7) [back to overview]	Persistently Elevated Serum Estradiol Level Outside the Post-menopausal Range
NCT00698035 (7) [back to overview]	Total Testosterone Levels
NCT00698035 (7) [back to overview]	Sexual Satisfaction
NCT00698035 (7) [back to overview]	Sexual Quality of Life
NCT00698035 (7) [back to overview]	Serum Estradiol (E2)
NCT00698035 (7) [back to overview]	Matched E2 by Commercial and Research (RIA) Analyses
NCT00741858 (1) [back to overview]	Physical Health Quality of Life
NCT00745901 (20) [back to overview]	Number of Days of Total Blood Loss - Cycle 2
NCT00745901 (20) [back to overview]	Number of Days of Total Blood Loss - Cycle 3
NCT00745901 (20) [back to overview]	Number of Days of Unscheduled Blood Loss - Cycle 2
NCT00745901 (20) [back to overview]	Number of Days of Unscheduled Blood Loss - Cycle 3
NCT00745901 (20) [back to overview]	Number of Participants With Breakthrough Bleeding/Spotting Cycle 1
NCT00745901 (20) [back to overview]	Number of Days of Scheduled Blood Loss - Cycle 3
NCT00745901 (20) [back to overview]	Number of Participants With Breakthrough Bleeding/Spotting Cycle 2
NCT00745901 (20) [back to overview]	Number of Participants With Breakthrough Bleeding/Spotting Cycle 3
NCT00745901 (20) [back to overview]	Number of Participants With Unscheduled Bleeding Cycle 1
NCT00745901 (20) [back to overview]	Number of Participants With Unscheduled Bleeding Cycle 2
NCT00745901 (20) [back to overview]	Number of Days of Scheduled Blood Loss - Cycle 1
NCT00745901 (20) [back to overview]	Number of Participants With Unscheduled Bleeding Cycle 3
NCT00745901 (20) [back to overview]	Overall Number of Days of Scheduled Blood Loss
NCT00745901 (20) [back to overview]	Overall Number of Days of Total Blood Loss
NCT00745901 (20) [back to overview]	Overall Number of Days of Unscheduled Blood Loss
NCT00745901 (20) [back to overview]	Number of Days of Scheduled Blood Loss - Cycle 2
NCT00745901 (20) [back to overview]	Number of Participants With the Indicated Number of Unscheduled Blood Loss Episodes
NCT00745901 (20) [back to overview]	Patient Satisfaction - Overall
NCT00745901 (20) [back to overview]	Number of Days of Unscheduled Blood Loss - Cycle 1
NCT00745901 (20) [back to overview]	Number of Days of Total Blood Loss - Cycle 1
NCT00754065 (117) [back to overview]	Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 13
NCT00754065 (117) [back to overview]	Maximum Length of Spotting-only Episodes in Reference Period 3
NCT00754065 (117) [back to overview]	Percentage of Participants With at Least 1 Intracyclic Bleeding Episode at Cycles 2 to 6
NCT00754065 (117) [back to overview]	Maximum Length of Spotting-only Episodes in Reference Period 2
NCT00754065 (117) [back to overview]	Maximum Length of Spotting-only Episodes in Reference Period 1
NCT00754065 (117) [back to overview]	Maximum Length of Intracyclic Bleeding Episodes at Cycle 6
NCT00754065 (117) [back to overview]	Maximum Length of Intracyclic Bleeding Episodes at Cycle 3
NCT00754065 (117) [back to overview]	Maximum Length of Intracyclic Bleeding Episodes at Cycle 13
NCT00754065 (117) [back to overview]	Maximum Length of Intracyclic Bleeding Episodes at Cycle 1
NCT00754065 (117) [back to overview]	Maximum Length of Bleeding / Spotting Episodes in Reference Period 4
NCT00754065 (117) [back to overview]	Change From Baseline to Cycle 13 in the Average of the Three Highest VAS Values of the Hormone Withdrawal-associated Symptoms Pelvic Pain or Headache During Cycle Days 22 to 28
NCT00754065 (117) [back to overview]	Change From Baseline to Cycle 3 in the Average of the Three Highest VAS Values of the Hormone Withdrawal-associated Symptoms Pelvic Pain or Headache During Cycle Days 22 to 28
NCT00754065 (117) [back to overview]	Difference in Duration Between Longest and Shortest Bleeding / Spotting Episodes in Reference Period 1
NCT00754065 (117) [back to overview]	Difference in Duration Between Longest and Shortest Bleeding / Spotting Episodes in Reference Period 2
NCT00754065 (117) [back to overview]	Difference in Duration Between Longest and Shortest Bleeding / Spotting Episodes in Reference Period 3
NCT00754065 (117) [back to overview]	Difference in Duration Between Longest and Shortest Bleeding / Spotting Episodes in Reference Period 4
NCT00754065 (117) [back to overview]	Difference in Duration Between Longest and Shortest Spotting-only Episodes in Reference Period 1
NCT00754065 (117) [back to overview]	Difference in Duration Between Longest and Shortest Spotting-only Episodes in Reference Period 2
NCT00754065 (117) [back to overview]	Difference in Duration Between Longest and Shortest Spotting-only Episodes in Reference Period 3
NCT00754065 (117) [back to overview]	Difference in Duration Between Longest and Shortest Spotting-only Episodes in Reference Period 4
NCT00754065 (117) [back to overview]	Length of Withdrawal Bleeding Episodes at Cycle 1
NCT00754065 (117) [back to overview]	Length of Withdrawal Bleeding Episodes at Cycle 13
NCT00754065 (117) [back to overview]	Length of Withdrawal Bleeding Episodes at Cycle 3
NCT00754065 (117) [back to overview]	Length of Withdrawal Bleeding Episodes at Cycle 6
NCT00754065 (117) [back to overview]	Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 1
NCT00754065 (117) [back to overview]	Number of Intracyclic Bleeding Episodes at Cycle 6
NCT00754065 (117) [back to overview]	Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 3
NCT00754065 (117) [back to overview]	Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 6
NCT00754065 (117) [back to overview]	Maximum Length of Bleeding / Spotting Episodes in Reference Period 1
NCT00754065 (117) [back to overview]	Maximum Length of Bleeding / Spotting Episodes in Reference Period 2
NCT00754065 (117) [back to overview]	Maximum Length of Bleeding / Spotting Episodes in Reference Period 3
NCT00754065 (117) [back to overview]	Mean Length of Spotting-only Episodes in Reference Period 3
NCT00754065 (117) [back to overview]	Mean Length of Spotting-only Episodes in Reference Period 4
NCT00754065 (117) [back to overview]	Number of Bleeding / Spotting Episodes in Reference Period 1
NCT00754065 (117) [back to overview]	Number of Bleeding / Spotting Episodes in Reference Period 2
NCT00754065 (117) [back to overview]	Number of Bleeding / Spotting Episodes in Reference Period 3
NCT00754065 (117) [back to overview]	Number of Bleeding / Spotting Episodes in Reference Period 4
NCT00754065 (117) [back to overview]	Number of Days With Bleeding or Spotting in Reference Period 1
NCT00754065 (117) [back to overview]	Number of Days With Bleeding or Spotting in Reference Period 2
NCT00754065 (117) [back to overview]	Number of Days With Bleeding or Spotting in Reference Period 3
NCT00754065 (117) [back to overview]	Number of Days With Bleeding or Spotting in Reference Period 4
NCT00754065 (117) [back to overview]	Number of Days With Spotting-only in Reference Period 1
NCT00754065 (117) [back to overview]	Number of Days With Spotting-only in Reference Period 2
NCT00754065 (117) [back to overview]	Number of Days With Spotting-only in Reference Period 3
NCT00754065 (117) [back to overview]	Number of Days With Spotting-only in Reference Period 4
NCT00754065 (117) [back to overview]	Number of Intracyclic Bleeding Days at Cycle 1
NCT00754065 (117) [back to overview]	Number of Intracyclic Bleeding Days at Cycle 13
NCT00754065 (117) [back to overview]	Number of Intracyclic Bleeding Days at Cycle 3
NCT00754065 (117) [back to overview]	Number of Intracyclic Bleeding Days at Cycle 6
NCT00754065 (117) [back to overview]	Number of Intracyclic Bleeding Episodes at Cycle 1
NCT00754065 (117) [back to overview]	Number of Intracyclic Bleeding Episodes at Cycle 13
NCT00754065 (117) [back to overview]	Number of Intracyclic Bleeding Episodes at Cycle 3
NCT00754065 (117) [back to overview]	Number of Spotting-only Episodes in Reference Period 1
NCT00754065 (117) [back to overview]	Number of Spotting-only Episodes in Reference Period 2
NCT00754065 (117) [back to overview]	Number of Spotting-only Episodes in Reference Period 3
NCT00754065 (117) [back to overview]	Number of Spotting-only Episodes in Reference Period 4
NCT00754065 (117) [back to overview]	Onset of Withdrawal Bleeding Episodes at Cycle 1
NCT00754065 (117) [back to overview]	Onset of Withdrawal Bleeding Episodes at Cycle 13
NCT00754065 (117) [back to overview]	Onset of Withdrawal Bleeding Episodes at Cycle 3
NCT00754065 (117) [back to overview]	Onset of Withdrawal Bleeding Episodes at Cycle 6
NCT00754065 (117) [back to overview]	The Change in Average of the 3 Highest Visual Analog Scale (VAS) Values of the Hormone Withdrawal-associated Symptoms Pelvic Pain or Headache During Cycle Days 22 to 28 From Baseline to Cycle 6
NCT00754065 (117) [back to overview]	The Change of Pelvic Pain or Headache as Determined by the Highest Visual Analog Scale (VAS) Values During Cycle Days 22 to 28 From Baseline to Cycle 6
NCT00754065 (117) [back to overview]	Change From Baseline to Cycle 13 in the Number of Days With at Least Moderate Pain/Intensity of Individual Hormone-related Symptoms During Cycle Days 1-21
NCT00754065 (117) [back to overview]	Change From Baseline to Cycle 13 in the Number of Days With at Least Moderate Pain/Intensity of Individual Hormone-related Symptoms During the Hormone-free Interval Cycle Days 27 to 28 for EV/DNG and Cycle Days 22 to 28 for EE/NGM
NCT00754065 (117) [back to overview]	Change From Baseline to Cycle 13 in the Number of Days With at Least Moderate Pain/Intensity of Other Hormone-related Symptoms During Cycle Days 22-28
NCT00754065 (117) [back to overview]	Change From Baseline to Cycle 6 in the Number of Days With at Least Moderate Pain/Intensity of Individual Hormone-related Symptoms During Cycle Days 1-21
NCT00754065 (117) [back to overview]	Change From Baseline to Cycle 6 in the Number of Days With at Least Moderate Pain/Intensity of Individual Hormone-related Symptoms During the Hormone-free Interval Cycle Days 27 to 28 for EV/DNG and Cycle Days 22 to 28 for EE/NGM
NCT00754065 (117) [back to overview]	Change From Baseline to Cycle 6 in the Number of Days With at Least Moderate Pain/Intensity of Other Hormone-related Symptoms During Cycle Days 22-28
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 13 in Psychological General Well-Being Index (PGWBI)
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI)
NCT00754065 (117) [back to overview]	Percentage of Participants by Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 1
NCT00754065 (117) [back to overview]	Percentage of Participants by Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 13
NCT00754065 (117) [back to overview]	Percentage of Participants by Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 3
NCT00754065 (117) [back to overview]	Percentage of Participants by Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 6
NCT00754065 (117) [back to overview]	Percentage of Participants With / Without Withdrawal Bleeding at Cycle 1
NCT00754065 (117) [back to overview]	Percentage of Participants With / Without Withdrawal Bleeding at Cycle 13
NCT00754065 (117) [back to overview]	Percentage of Participants With / Without Withdrawal Bleeding at Cycle 3
NCT00754065 (117) [back to overview]	Percentage of Participants With / Without Withdrawal Bleeding at Cycle 6
NCT00754065 (117) [back to overview]	Percentage of Participants With at Least 1 Intracyclic Bleeding Episode at Cycles 2 to 13
NCT00754065 (117) [back to overview]	Percentage of Participants With Improvement in the Investigator's Assessment in Clinical Global Impression (CGI) at Cycle 13
NCT00754065 (117) [back to overview]	Percentage of Participants With Improvement in the Investigator's Assessment in Clinical Global Impression (CGI) at Cycle 6
NCT00754065 (117) [back to overview]	Percentage of Participants With Improvement in the Participant's Assessment in Clinical Global Impression (CGI) at Cycle 13
NCT00754065 (117) [back to overview]	Percentage of Participants With Improvement in the Participant's Assessment in Clinical Global Impression (CGI) at Cycle 6
NCT00754065 (117) [back to overview]	Percentage of Participants With no Increase in Rescue Medication and VAS Decrease During Cycle Days 22 to 28 From Baseline to Cycle 6
NCT00754065 (117) [back to overview]	Percentage of Participants With Presence or Absence of Intracyclic Bleeding at Cycle 1
NCT00754065 (117) [back to overview]	Percentage of Participants With Presence or Absence of Intracyclic Bleeding at Cycle 13
NCT00754065 (117) [back to overview]	Percentage of Participants With Presence or Absence of Intracyclic Bleeding at Cycle 3
NCT00754065 (117) [back to overview]	Percentage of Participants With Presence or Absence of Intracyclic Bleeding at Cycle 6
NCT00754065 (117) [back to overview]	The Change From Baseline to Cycle 13 in the Number of Ibuprofen Tablets Used as Rescue Medication
NCT00754065 (117) [back to overview]	The Change From Baseline to Cycle 6 in the Number of Ibuprofen Tablets Used as Rescue Medication
NCT00754065 (117) [back to overview]	Mean Length of Bleeding / Spotting Episodes in Reference Period 3
NCT00754065 (117) [back to overview]	Mean Length of Spotting-only Episodes in Reference Period 1
NCT00754065 (117) [back to overview]	Mean Length of Bleeding / Spotting Episodes in Reference Period 4
NCT00754065 (117) [back to overview]	Mean Length of Bleeding / Spotting Episodes in Reference Period 2
NCT00754065 (117) [back to overview]	Mean Length of Bleeding / Spotting Episodes in Reference Period 1
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Work
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Social Relationship
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - School/Course Work
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Physical Health
NCT00754065 (117) [back to overview]	Mean Length of Spotting-only Episodes in Reference Period 2
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Participant Feeling
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Overall Life Satisfaction and Contentment
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Leisure Time Activities
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Item Satisfaction
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Household Duties
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - General Activities
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 13 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Work
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 13 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Social Relationship
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 13 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - School/Course Work
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 13 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Physical Health
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 13 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Participant Feeling
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 13 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Overall Life Satisfaction and Contentment
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 13 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Leisure Time Activities
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 13 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Item Satisfaction
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 13 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - Household Duties
NCT00754065 (117) [back to overview]	Mean Change From Baseline to Cycle 13 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) - General Activities
NCT00754065 (117) [back to overview]	Maximum Length of Spotting-only Episodes in Reference Period 4
NCT00799708 (2) [back to overview]	Change From Baseline in Minor Gland Salivary Flow Rate After Treatment With 2 mg Estradiol vs Placebo at Day 7.
NCT00799708 (2) [back to overview]	Change From Baseline in Estrogen Receptor Beta (ERbeta) -Specific Gene Signature After Treatment With 2 mg, 0.5 mg, or no Estradiol (Placebo) at Day 7
NCT00816556 (3) [back to overview]	Change in Vulvovaginal Atrophy Questionnaire (VVAQ) Scores From Baseline to Week 12
NCT00816556 (3) [back to overview]	Change in Serum Estrone (E1) Levels Between Baseline, 2 Weeks, and 12 Weeks
NCT00816556 (3) [back to overview]	Change in Serum Estradiol (E2) Levels Between Baseline, 2 Weeks, and 12 Weeks
NCT00820664 (1) [back to overview]	Immunohistochemistry (IHC) Proliferative Effects Measurement
NCT00837616 (10) [back to overview]	Lipids Concentrations After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months
NCT00837616 (10) [back to overview]	Serum Estrone Sulfate Concentrations After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months
NCT00837616 (10) [back to overview]	Change in Fat Free Mass From Baseline at 12 Months
NCT00837616 (10) [back to overview]	Rates of Lipid Oxidation After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months
NCT00837616 (10) [back to overview]	Changes in Insulin Growth Factor-I From Baseline at 12 Months
NCT00837616 (10) [back to overview]	Change in Weight From Baseline at 12 Months
NCT00837616 (10) [back to overview]	Change in Percent Fat Mass From Baseline in 12 Months
NCT00837616 (10) [back to overview]	Change in Body Mass Index From Baseline at 12 Months
NCT00837616 (10) [back to overview]	Serum 17B Estradiol Concentrations After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months
NCT00837616 (10) [back to overview]	Serum Estrone Concentrations After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months
NCT00859508 (1) [back to overview]	Absence of Cerebrospinal Fluid (CSF) Fistula and Pseudomeningocele
NCT00909857 (68) [back to overview]	Vitality as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
NCT00909857 (68) [back to overview]	Participants With Improvement in Participants' Assessment in the Clinical Global Impression
NCT00909857 (68) [back to overview]	Participants With Improvement in the Investigators' Assessment in the Clinical Global Impression
NCT00909857 (68) [back to overview]	Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Baseline Cycle
NCT00909857 (68) [back to overview]	Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Cycle 2
NCT00909857 (68) [back to overview]	Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Final Examination
NCT00909857 (68) [back to overview]	Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Screening
NCT00909857 (68) [back to overview]	Percentage of Participants Satisfied With Study Treatment
NCT00909857 (68) [back to overview]	Percentage of Participants With Interference of Dysmenorrheic Pain With Work/School and Social or Other Activity (Entire Evaluation Period Used)
NCT00909857 (68) [back to overview]	Percentage of Participants With Interference of Dysmenorrheic Pain With Work/School and Social or Other Activity (Only Bleeding Episodes Used Including the Two Days Before)
NCT00909857 (68) [back to overview]	Percentage of Participants With Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 1
NCT00909857 (68) [back to overview]	Percentage of Participants With Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 3
NCT00909857 (68) [back to overview]	Maximum Length of Spotting Only Episodes
NCT00909857 (68) [back to overview]	Maximum Length of Bleeding or Spotting Episodes
NCT00909857 (68) [back to overview]	Mean Length of Bleeding or Spotting Episodes
NCT00909857 (68) [back to overview]	Mean Length of Spotting Only Episodes
NCT00909857 (68) [back to overview]	Mental Health as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
NCT00909857 (68) [back to overview]	Mental Health as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
NCT00909857 (68) [back to overview]	Number of Days With Bleeding or Spotting
NCT00909857 (68) [back to overview]	Number of Days With Spotting-only
NCT00909857 (68) [back to overview]	Number of Episodes With Bleeding or Spotting
NCT00909857 (68) [back to overview]	Number of Episodes With Spotting-only
NCT00909857 (68) [back to overview]	Number of Intracyclic Bleeding Days at Cycle 1
NCT00909857 (68) [back to overview]	Number of Intracyclic Bleeding Days at Cycle 3
NCT00909857 (68) [back to overview]	Number of Intracyclic Bleeding Episodes at Cycle 1
NCT00909857 (68) [back to overview]	Number of Intracyclic Bleeding Episodes at Cycle 3
NCT00909857 (68) [back to overview]	Role Physical as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
NCT00909857 (68) [back to overview]	Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 3
NCT00909857 (68) [back to overview]	Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 1
NCT00909857 (68) [back to overview]	Length of Withdrawal Bleeding Episodes at Cycle 3
NCT00909857 (68) [back to overview]	Length of Withdrawal Bleeding Episodes at Cycle 1
NCT00909857 (68) [back to overview]	General Health as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
NCT00909857 (68) [back to overview]	General Health as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
NCT00909857 (68) [back to overview]	Difference in Duration Between Longest and Shortest Spotting Only Episode
NCT00909857 (68) [back to overview]	Difference in Duration Between Longest and Shortest Bleeding or Spotting Episode
NCT00909857 (68) [back to overview]	Change Between Baseline Evaluation Period and Treatment Evaluation Period in the Sum of Score Points of Dysmenorrheic Pain
NCT00909857 (68) [back to overview]	Change Between Baseline Evaluation Period and Treatment Evaluation Period in the Number of Days With Dysmenorrheic Pain
NCT00909857 (68) [back to overview]	Change Between Baseline Evaluation Period and Treatment Evaluation Period in Rescue Medication Use (Only Bleeding Episodes Used Including the Two Days Before the Episode)
NCT00909857 (68) [back to overview]	Change Between Baseline Evaluation Period and Treatment Evaluation Period in Rescue Medication Use (Entire Evaluation Period Used)
NCT00909857 (68) [back to overview]	Change Between Baseline Evaluation Period and Treatment Evaluation Period in Number of Days With Pelvic Pain Independent of Occurrence of Vaginal Bleeding
NCT00909857 (68) [back to overview]	Maximum Length of Intracyclic Bleeding Episodes at Cycle 1
NCT00909857 (68) [back to overview]	Change Between Baseline Evaluation Period and Treatment Evaluation Period in Number of Days With Pelvic Pain During Unscheduled Bleeding
NCT00909857 (68) [back to overview]	Bodily Pain as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
NCT00909857 (68) [back to overview]	Bodily Pain as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
NCT00909857 (68) [back to overview]	Social Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
NCT00909857 (68) [back to overview]	Social Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
NCT00909857 (68) [back to overview]	Vitality as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
NCT00909857 (68) [back to overview]	Onset of Withdrawal Bleeding Episodes at Cycle 1
NCT00909857 (68) [back to overview]	Onset of Withdrawal Bleeding Episodes at Cycle 3
NCT00909857 (68) [back to overview]	Maximum Length of Intracyclic Bleeding Episodes at Cycle 3
NCT00909857 (68) [back to overview]	Own Costs of Acupuncture Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
NCT00909857 (68) [back to overview]	Own Costs of Alternative Medicine Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
NCT00909857 (68) [back to overview]	Own Costs of Herbs/Teas Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
NCT00909857 (68) [back to overview]	Own Costs of Massages Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
NCT00909857 (68) [back to overview]	Own Costs of Medical Counseling Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
NCT00909857 (68) [back to overview]	Own Costs of Pain Medication Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
NCT00909857 (68) [back to overview]	Own Costs of Physiotherapy Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
NCT00909857 (68) [back to overview]	Own Costs of Vitamins Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
NCT00909857 (68) [back to overview]	Percentage of Participants With Intracyclic Bleeding at Cycle 1
NCT00909857 (68) [back to overview]	Percentage of Participants With Intracyclic Bleeding at Cycle 3
NCT00909857 (68) [back to overview]	Percentage of Participants With Withdrawal Bleeding at Cycle 1
NCT00909857 (68) [back to overview]	Percentage of Participants With Withdrawal Bleeding at Cycle 3
NCT00909857 (68) [back to overview]	Physical Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
NCT00909857 (68) [back to overview]	Physical Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
NCT00909857 (68) [back to overview]	Role Emotional as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
NCT00909857 (68) [back to overview]	Role Emotional as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
NCT00909857 (68) [back to overview]	Role Physical as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
NCT00909857 (68) [back to overview]	Other Own Costs Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
NCT00924560 (13) [back to overview]	Change From Baseline in Lumbar Spine Bone Mineral Density
NCT00924560 (13) [back to overview]	Change From Baseline in Proximal Femur Bone Mineral Content (BMC)
NCT00924560 (13) [back to overview]	Change From Baseline in Serum Deoxypyridinoline
NCT00924560 (13) [back to overview]	Change From Baseline in Serum Osteocalcin
NCT00924560 (13) [back to overview]	Change From Baseline in Serum Procollagen 1 N-terminal Propeptide
NCT00924560 (13) [back to overview]	Change From Baseline in Serum Type I Collagen N-telopeptide
NCT00924560 (13) [back to overview]	Change From Baseline in Total Body Bone Mineral Content (BMC)
NCT00924560 (13) [back to overview]	Change From Baseline in Total Body Bone Mineral Density
NCT00924560 (13) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT00924560 (13) [back to overview]	Change From Baseline in Proximal Femur Bone Mineral Density
NCT00924560 (13) [back to overview]	Percent Change From Baseline to 12 Months in Lumbar Spine Bone Mineral Density (BMD)
NCT00924560 (13) [back to overview]	Change From Baseline in Bone-specific Alkaline Phosphatase
NCT00924560 (13) [back to overview]	Change From Baseline in Lumbar Spine Bone Mineral Content (BMC)
NCT00932321 (2) [back to overview]	Pregnancy Rate (Expressed as Pearl Index) for Women 18 to 45 Years Old, MITT Population
NCT00932321 (2) [back to overview]	Mean Number of Intracyclic Bleeding (IB)/Spotting Days in Cycles 2-6, MITT Population
NCT00946192 (2) [back to overview]	Change in Lumbar Bone Mineral Density
NCT00946192 (2) [back to overview]	Change in Total Volumetric Bone Mineral Density (Tibia)
NCT00997893 (5) [back to overview]	Changes in STAI-6 Scores Before and After Psychosocial Stressor Over Time
NCT00997893 (5) [back to overview]	Memory for Emotionally Valent Words and Neutral Words
NCT00997893 (5) [back to overview]	Change in Verbal Memory, Delayed Recall
NCT00997893 (5) [back to overview]	Change in Verbal Memory, Immediate Recall
NCT00997893 (5) [back to overview]	Change in STAI-6 Score
NCT01015677 (5) [back to overview]	Number of Participants Who Discontinued Study Drug Due to an AE
NCT01015677 (5) [back to overview]	Change From Baseline in Follicle-stimulating Hormone (FSH) Level at Week 4
NCT01015677 (5) [back to overview]	Percent Change From Baseline in the Weekly Hot Flash Severity Score (Combining Severe and Very Severe Score) at Week 4
NCT01015677 (5) [back to overview]	Number of Participants Who Experienced at Least One or More Adverse Events (AE)
NCT01015677 (5) [back to overview]	Percent Change From Baseline in the Number of Weekly Moderate to Very Severe Hot Flashes (Excluding Outliers) at Week 4
NCT01023178 (1) [back to overview]	Estradiol
NCT01070979 (7) [back to overview]	Mean Change From Baseline in Total Urogenital Symptom Score, Week 4, ITT Population
NCT01070979 (7) [back to overview]	Change From Baseline in Total Urogenital Symptom Score, Week 12, ITT Population
NCT01070979 (7) [back to overview]	Mean Change From Baseline in the Number of Moderate to Severe Hot Flushes, Week 12, ITT Population
NCT01070979 (7) [back to overview]	Mean Change From Baseline in the Number of Moderate to Severe Hot Flushes, Week 4, ITT (Intention to Treat) Population
NCT01070979 (7) [back to overview]	Mean Change From Baseline in the Severity of Moderate to Severe Hot Flushes, Week 12, ITT Population
NCT01070979 (7) [back to overview]	Mean Change From Baseline in the Severity of Moderate to Severe Hot Flushes, Week 4, ITT Population
NCT01070979 (7) [back to overview]	Change From Baseline in Total Urogenital Symptom Score, Week 8, ITT Population
NCT01109979 (1) [back to overview]	Brachial Artery Reactivity % Flow Mediated Dilation (BAR %FMD)
NCT01153581 (3) [back to overview]	Baroreceptor Function
NCT01153581 (3) [back to overview]	Skin Microvascular Responses
NCT01153581 (3) [back to overview]	Orthostatic Tolerance
NCT01157182 (21) [back to overview]	AUC0-t for Uncorrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01157182 (21) [back to overview]	AUC0-t for Norethindrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01157182 (21) [back to overview]	Cmax for Corrected Unconjugated Estrone(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01157182 (21) [back to overview]	AUC0-t for Corrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01157182 (21) [back to overview]	AUC0-t for Corrected Unconjugated Estradiol.(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01157182 (21) [back to overview]	Cmax for Norethindrone(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01157182 (21) [back to overview]	Cmax for Uncorrected Total Estrone(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01157182 (21) [back to overview]	Cmax for Uncorrected Unconjugated Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01157182 (21) [back to overview]	Cmax for Uncorrected Unconjugated Estrone(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01157182 (21) [back to overview]	AUC0-t for Corrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01157182 (21) [back to overview]	AUC0-t for Uncorrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01157182 (21) [back to overview]	AUC0-inf for Uncorrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01157182 (21) [back to overview]	AUC0-inf for Norethindrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01157182 (21) [back to overview]	AUC0-inf for Corrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01157182 (21) [back to overview]	AUC0-inf for Corrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01157182 (21) [back to overview]	Cmax for Corrected Unconjugated Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01157182 (21) [back to overview]	AUC0-inf for Uncorrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01157182 (21) [back to overview]	AUC0-inf for Uncorrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01157182 (21) [back to overview]	Cmax for Corrected Total Estrone(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01157182 (21) [back to overview]	AUC0-t for Uncorrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01157182 (21) [back to overview]	AUC0-inf for Corrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01170390 (5) [back to overview]	EE Steady State After Randomization
NCT01170390 (5) [back to overview]	LNG AUC
NCT01170390 (5) [back to overview]	EE Steady State Baseline
NCT01170390 (5) [back to overview]	LNG AUC
NCT01170390 (5) [back to overview]	LNG Steady State at Baseline and Then Post-randomization
NCT01181726 (21) [back to overview]	Cmax of Uncorrected Total Estrone(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01181726 (21) [back to overview]	Cmax of Uncorrected Unconjugated Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01181726 (21) [back to overview]	Cmax of Uncorrected Unconjugated Estrone(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01181726 (21) [back to overview]	AUC0-t of Uncorrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01181726 (21) [back to overview]	AUC0-t of Norethindrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01181726 (21) [back to overview]	AUC0-t of Corrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01181726 (21) [back to overview]	AUC0-t of Uncorrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01181726 (21) [back to overview]	Cmax of Corrected Total Estrone(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01181726 (21) [back to overview]	Cmax of Corrected Unconjugated Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01181726 (21) [back to overview]	Cmax of Corrected Unconjugated Estrone(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01181726 (21) [back to overview]	Cmax of Norethindrone (Maximum Observed Concentration of Drug Substance in Plasma)
NCT01181726 (21) [back to overview]	AUC0-inf of Corrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01181726 (21) [back to overview]	AUC0-inf of Corrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01181726 (21) [back to overview]	AUC0-inf of Corrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01181726 (21) [back to overview]	AUC0-t of Uncorrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01181726 (21) [back to overview]	AUC0-inf of Norethindrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01181726 (21) [back to overview]	AUC0-inf of Uncorrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01181726 (21) [back to overview]	AUC0-inf of Uncorrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01181726 (21) [back to overview]	AUC0-inf of Uncorrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01181726 (21) [back to overview]	AUC0-t of Corrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01181726 (21) [back to overview]	AUC0-t of Corrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01182194 (6) [back to overview]	AUC0-inf of Ethinyl Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01182194 (6) [back to overview]	AUC0-t of Drospirenone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01182194 (6) [back to overview]	AUC0-t of Ethinyl Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01182194 (6) [back to overview]	Cmax of Ethinyl Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01182194 (6) [back to overview]	Cmax of Drospirenone(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01182194 (6) [back to overview]	AUC0-inf of Drospirenone(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01182207 (6) [back to overview]	Cmax of Drospirenone(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01182207 (6) [back to overview]	AUC0-t of Drospirenone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01182207 (6) [back to overview]	AUC0-inf of Ethinyl Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01182207 (6) [back to overview]	AUC0-inf of Drospirenone(Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT01182207 (6) [back to overview]	AUC0-t of Ethinyl Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT01182207 (6) [back to overview]	Cmax of Ethinyl Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)
NCT01253824 (4) [back to overview]	Comparing Progesterone AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))
NCT01253824 (4) [back to overview]	Comparing FSH AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))
NCT01253824 (4) [back to overview]	Comparing Estradiol AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))
NCT01253824 (4) [back to overview]	Comparing LH AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))
NCT01268046 (1) [back to overview]	Functional Magnetic Resonance Imaging (fMRI) Changes in Response to Estrogen and Aging - Dorsolateral Pre-frontal Cortex (DLPFC)
NCT01297348 (2) [back to overview]	Number of Idiopathic Venous Thromboembolism (VTE) Cases and Matched Controls
NCT01297348 (2) [back to overview]	Incidence Rate of Idiopathic Venous Thromboembolism (VTE)
NCT01301183 (2) [back to overview]	Change in Trabecular Number at the Ultradistal Radius Over a 12-month Period
NCT01301183 (2) [back to overview]	Change in Bone Density Over a 12-month Period
NCT01340625 (6) [back to overview]	AUC0-inf of Norethindrone
NCT01340625 (6) [back to overview]	AUC0-inf of Ethinyl Estradiol
NCT01340625 (6) [back to overview]	Cmax of Norethindrone
NCT01340625 (6) [back to overview]	Cmax of Ethinyl Estradiol
NCT01340625 (6) [back to overview]	AUC0-t of Norethindrone
NCT01340625 (6) [back to overview]	AUC0-t of Ethinyl Estradiol
NCT01344369 (6) [back to overview]	AUC0-inf of Ethinyl Estradiol
NCT01344369 (6) [back to overview]	AUC0-inf of Norethindrone
NCT01344369 (6) [back to overview]	AUC0-t of Ethinyl Estradiol
NCT01344369 (6) [back to overview]	AUC0-t of Norethindrone
NCT01344369 (6) [back to overview]	Cmax of Norethindrone
NCT01344369 (6) [back to overview]	Cmax of Ethinyl Estradiol
NCT01388491 (14) [back to overview]	Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Endogenous Thrombin Potential (EPT)-Based Activated Protein-C (APC) Resistance
NCT01388491 (14) [back to overview]	Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Factor II Activity
NCT01388491 (14) [back to overview]	Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Thyroid-Stimulating Hormone (TSH)
NCT01388491 (14) [back to overview]	Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Activated Partial Thromboplastin Time (APTT)-Based Activated Protein-C (APC) Resistance
NCT01388491 (14) [back to overview]	Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Antithrombin
NCT01388491 (14) [back to overview]	Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Corticosteroid-Binding Globulin
NCT01388491 (14) [back to overview]	Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Sex Hormone Binding Globulin
NCT01388491 (14) [back to overview]	Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in D-Dimer
NCT01388491 (14) [back to overview]	Least Squares Mean Change From Baseline Over the 6-Month Period in Protein S Total Antigen
NCT01388491 (14) [back to overview]	Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Prothrombin Fragment 1 + 2 Levels
NCT01388491 (14) [back to overview]	Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Protein C Activity
NCT01388491 (14) [back to overview]	Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Serum Random Total Cortisol
NCT01388491 (14) [back to overview]	Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Factor VIII
NCT01388491 (14) [back to overview]	Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Factor VII
NCT01389102 (2) [back to overview]	Mean Change in the Number of Moderate to Severe Vasomotor Symptoms Per Day
NCT01389102 (2) [back to overview]	Mean Change the Severity of Moderate to Severe Vasomotor Symptoms
NCT01418209 (8) [back to overview]	Perceived Hot Flash Interference (Hot Flash Related Daily Interference Scale; HFRDIS) -- Week 4
NCT01418209 (8) [back to overview]	Perceived Hot Flash Interference (Hot Flash Related Daily Interference Scale; HFRDIS) -- Week 8
NCT01418209 (8) [back to overview]	Severity of Hot Flashes -- Week 4
NCT01418209 (8) [back to overview]	Frequency of Hot Flashes (Vasomotor Symptom [VMS] Frequency) -- Week 4
NCT01418209 (8) [back to overview]	Frequency of Hot Flashes (Daily Vasomotor Symptom [VMS] Frequency) -- Week 8
NCT01418209 (8) [back to overview]	Bothersomeness of Hot Flashes -- Week 8
NCT01418209 (8) [back to overview]	Bothersomeness of Hot Flashes -- Week 4
NCT01418209 (8) [back to overview]	Severity of Hot Flashes -- Week 8
NCT01441635 (20) [back to overview]	Percentage of Participants With MBL < 80 mL and With a ≥ 50% Reduction From Baseline in MBL During the Last 28 Days of Treatment
NCT01441635 (20) [back to overview]	Change From Baseline to Month 3 in Percentage of Days With Any Uterine Bleeding
NCT01441635 (20) [back to overview]	Change From Baseline to Month 3 in Percentage of Days With Moderate to Very Heavy Bleeding
NCT01441635 (20) [back to overview]	Change From Baseline to Month 3 in Uterine Bleeding Score
NCT01441635 (20) [back to overview]	Change in Hemoglobin Concentration From Baseline to Month 3
NCT01441635 (20) [back to overview]	Percent Change From Baseline to Month 3 in Uterine Volume
NCT01441635 (20) [back to overview]	Percent Change From Baseline to Month 3 in Volume of the Largest Fibroid
NCT01441635 (20) [back to overview]	Percent Change From Baseline to the Last 28 Days of Treatment in Menstrual Blood Loss (MBL)
NCT01441635 (20) [back to overview]	Percentage of Participants With ≥ 25% Reduction in Uterine Volume at Month 3 / Final Visit
NCT01441635 (20) [back to overview]	Percentage of Participants With ≥ 25% Reduction in Volume of Largest Fibroid at Month 3 / Final Visit
NCT01441635 (20) [back to overview]	Percentage of Participants With a ≥ 50% Reduction From Baseline in MBL During the Last 28 Days of Treatment
NCT01441635 (20) [back to overview]	Percentage of Participants With Suppression of Bleeding (Spotting Allowed) or Amenorrhea During the Last 56 Days of Treatment
NCT01441635 (20) [back to overview]	Percentage of Participants With MBL < 80 mL During the Last 28 Days of Treatment
NCT01441635 (20) [back to overview]	Change From Baseline to Month 3 in the Physician Surgery Intention Questionnaire (PSIQ) Version 2.0
NCT01441635 (20) [back to overview]	Change From Baseline to Month 3 in the Subject Surgery Intention Questionnaire (SSIQ) Version 2.0
NCT01441635 (20) [back to overview]	Change From Baseline to Month 3 in the Uterine Fibroid Symptom Quality of Life Questionnaire (UFS-QoL)
NCT01441635 (20) [back to overview]	Change From Baseline to Month 3 in the Uterine Fibroids Daily Symptom Scale Scores
NCT01441635 (20) [back to overview]	Mean Change From Baseline to the Last 28 Days of Treatment in Menstrual Blood Loss (MBL)
NCT01441635 (20) [back to overview]	Percentage of Participants With Any Uterine Bleeding or Moderate to Very Heavy Uterine Bleeding at Month 3
NCT01441635 (20) [back to overview]	Percentage of Participants With No Change, Decrease From Baseline, or Increase From Baseline in Hemoglobin at Month 3
NCT01466673 (10) [back to overview]	Number of Participants With Abnormal Vaginal Blood Loss at Month 1, 3 and 6
NCT01466673 (10) [back to overview]	Number of Participants With Treatment Response at the End-of-Therapy by Participant's Self-Assessment at Month 6
NCT01466673 (10) [back to overview]	Number of Participants Non-Compliant With Therapy
NCT01466673 (10) [back to overview]	Percentage of Participants Showing Treatment Response on the Investigator's Global Assessment at Month 6
NCT01466673 (10) [back to overview]	Percentage of Participants With Categorical Score for Sebum Assessment at Month 1, 3 and 6
NCT01466673 (10) [back to overview]	Change From Baseline in Blood Pressure (BP) at Month 6
NCT01466673 (10) [back to overview]	Change From Baseline in Body Weight at Month 6
NCT01466673 (10) [back to overview]	Change From Baseline in Total and Each Type of Acne Lesions Count at Month 1
NCT01466673 (10) [back to overview]	Change From Baseline in Total and Each Type of Acne Lesions Count at Month 3
NCT01466673 (10) [back to overview]	Change From Baseline in Total and Each Type of Acne Lesions Count at Month 6
NCT01546454 (1) [back to overview]	Total to HDL Cholesterol Ratio
NCT01709318 (12) [back to overview]	Percentage of Participants With Ovulation Incidence, by Cycle
NCT01709318 (12) [back to overview]	Percentage of Participants With Breakthrough Bleeding and/or Spotting During Cycle 3
NCT01709318 (12) [back to overview]	Percentage of Participants With Any Drug-Related Serious Adverse Event
NCT01709318 (12) [back to overview]	Percentage of Participants Who Experienced At Least One Serious Adverse Event
NCT01709318 (12) [back to overview]	Percentage of Participants Who Experienced At Least One Drug-Related Adverse Event
NCT01709318 (12) [back to overview]	Percentage of Participants With Absence of Withdrawal Bleeding and/or Spotting During Cycle 2
NCT01709318 (12) [back to overview]	Percentage of Participants With Progesterone Concentrations >16 Nmol/L, by Cycle
NCT01709318 (12) [back to overview]	Intensity of Breakthrough Bleeding and/or Spotting During Cycle 3
NCT01709318 (12) [back to overview]	Intensity of Withdrawal Bleeding During Cycle 2
NCT01709318 (12) [back to overview]	Number of Participants With Venous or Arterial Thrombotic/Thromboembolic Events
NCT01709318 (12) [back to overview]	Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event
NCT01709318 (12) [back to overview]	Percentage of Participants Who Experienced At Least One Adverse Event
NCT01817530 (18) [back to overview]	Change in Bleeding Severity Scores From Baseline at the Final Month
NCT01817530 (18) [back to overview]	Mean Change in Hemoglobin Concentration From Baseline to Final Visit
NCT01817530 (18) [back to overview]	Mean Change in the Number of Bleeding Days From Baseline to Month 6
NCT01817530 (18) [back to overview]	Mean Change in the Number of Heavy Bleeding Days From Baseline to Month 6
NCT01817530 (18) [back to overview]	Percentage of Participants Who Achieved Amenorrhea During the Last 56 Days of Treatment
NCT01817530 (18) [back to overview]	Percentage of Participants Who Achieved an MBL Volume of < 80 mL at the Final Month
NCT01817530 (18) [back to overview]	Percentage of Participants With ≥ 25% Reduction From Baseline in Uterine Volume at Month 3, Month 6, and Final Visit
NCT01817530 (18) [back to overview]	Percentage of Participants Who Achieved Suppression of Bleeding During the Last 56 Days of Treatment
NCT01817530 (18) [back to overview]	Percentage of Participants With a ≥ 50% Reduction in MBL Volume From Baseline to the Final Month
NCT01817530 (18) [back to overview]	Percentage of Participants With a MBL Volume < 80 mL and a ≥ 50% Reduction in MBL Volume From Baseline During the Last 56 to 29 Days of Treatment
NCT01817530 (18) [back to overview]	Percentage of Participants With a MBL Volume < 80 mL and a ≥ 50% Reduction in MBL Volume From Baseline During the Last 84 to 57 Days of Treatment
NCT01817530 (18) [back to overview]	Percentage of Participants With a Menstrual Blood Loss (MBL) Volume of < 80 mL at the Final Month and a ≥ 50% Reduction in MBL Volume From Baseline to the Final Month
NCT01817530 (18) [back to overview]	Change From Baseline to Each Month in Non-Bleeding Uterine Fibroids Symptom (NBUFSQ) Questionnaire
NCT01817530 (18) [back to overview]	Mean Percentage Change From Baseline in Primary Fibroid Volume at Month 3, Month 6, and Final Visit
NCT01817530 (18) [back to overview]	Mean Percentage Change From Baseline in Total Fibroid Volume at Month 3, Month 6, and Final Visit
NCT01817530 (18) [back to overview]	Mean Percentage Change From Baseline in Uterine Volume at Month 3, Month 6, and Final Visit
NCT01817530 (18) [back to overview]	Percentage of Participants With ≥ 25% Reduction From Baseline in Primary Fibroid Volume at Month 3, Month 6, and Final Visit
NCT01817530 (18) [back to overview]	Percentage of Participants With ≥ 25% Reduction From Baseline in Total Fibroid Volume at Month 3, Month 6, and Final Visit
NCT01942668 (210) [back to overview]	Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 2 (MITT-VMS)
NCT01942668 (210) [back to overview]	Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 3 (MITT-VMS)
NCT01942668 (210) [back to overview]	Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 4 (MITT-VMS)
NCT01942668 (210) [back to overview]	Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 5 (MITT-VMS)
NCT01942668 (210) [back to overview]	Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 6 (MITT-VMS)
NCT01942668 (210) [back to overview]	Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 7 (MITT-VMS)
NCT01942668 (210) [back to overview]	Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 8 (MITT-VMS)
NCT01942668 (210) [back to overview]	Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 9 (MITT-VMS)
NCT01942668 (210) [back to overview]	Frequency of Moderate to Severe Vasomotor Symptoms - Week 1 (MITT-VMS)
NCT01942668 (210) [back to overview]	Frequency of Moderate to Severe Vasomotor Symptoms - Week 10 (MITT-VMS)
NCT01942668 (210) [back to overview]	Frequency of Moderate to Severe Vasomotor Symptoms - Week 11 (MITT-VMS)
NCT01942668 (210) [back to overview]	Frequency of Moderate to Severe Vasomotor Symptoms - Week 12 (MITT-VMS)
NCT01942668 (210) [back to overview]	Frequency of Moderate to Severe Vasomotor Symptoms - Week 2 (MITT-VMS)
NCT01942668 (210) [back to overview]	Frequency of Moderate to Severe Vasomotor Symptoms - Week 3 (MITT-VMS)
NCT01942668 (210) [back to overview]	Frequency of Moderate to Severe Vasomotor Symptoms - Week 4 (MITT-VMS)
NCT01942668 (210) [back to overview]	Frequency of Moderate to Severe Vasomotor Symptoms - Week 5 (MITT-VMS)
NCT01942668 (210) [back to overview]	Frequency of Moderate to Severe Vasomotor Symptoms - Week 6 (MITT-VMS)
NCT01942668 (210) [back to overview]	Frequency of Moderate to Severe Vasomotor Symptoms - Week 7 (MITT-VMS)
NCT01942668 (210) [back to overview]	Frequency of Moderate to Severe Vasomotor Symptoms - Week 8 (MITT-VMS)
NCT01942668 (210) [back to overview]	Frequency of Moderate to Severe Vasomotor Symptoms - Week 9 (MITT-VMS)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 12 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 12 - (MITT)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 6 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 6 - (MITT)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Week 12 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Week 12 - (MITT)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 12 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 12 - (MITT)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 6 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 6 - (MITT)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Week 12 - (MITT)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Week 12 (MITT-VMS)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 12 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 12 - (MITT)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 6 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 6 - (MITT)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Week 12 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Week 12 - (MITT)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Month 12 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Month 12 - (MITT)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Month 6 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Week 12 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Week 12 - (MITT)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Month 12 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Month 12 - (MITT)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Month 6 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Month 6 - (MITT)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Week 12 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Week 12 - (MITT)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 12 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 12 - (MITT)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 6 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 6 - (MITT)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Week 12 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Week 12 - (MITT)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Month 12 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Month 12 - (MITT)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Month 6 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Month 6 - (MITT)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Week 12 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Week 12 - (MITT)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Optimal Sleep - Month 12 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Optimal Sleep - Month 12 - (MITT)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Optimal Sleep - Month 6 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Optimal Sleep - Month 6 - (MITT)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Optimal Sleep - Week 12 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Optimal Sleep - Week 12 - (MITT)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Sleep Problems Index II - Month 6 - (MITT)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 12 (MITT-VMS)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 12 (MITT)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 6 (MITT-VMS)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 6 (MITT)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Week 12 (MITT-VMS)
NCT01942668 (210) [back to overview]	Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Week 12 (MITT)
NCT01942668 (210) [back to overview]	Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 12 (MITT-VMS)
NCT01942668 (210) [back to overview]	Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 12 (MITT)
NCT01942668 (210) [back to overview]	Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 6 (MITT-VMS)
NCT01942668 (210) [back to overview]	Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 6 (MITT)
NCT01942668 (210) [back to overview]	Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Week 12 (MITT-VMS)
NCT01942668 (210) [back to overview]	Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Week 12 (MITT)
NCT01942668 (210) [back to overview]	Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 12 (MITT-VMS)
NCT01942668 (210) [back to overview]	Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 12 (MITT)
NCT01942668 (210) [back to overview]	Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 6 (MITT-VMS)
NCT01942668 (210) [back to overview]	Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 6 (MITT)
NCT01942668 (210) [back to overview]	Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Week 12 (MITT-VMS)
NCT01942668 (210) [back to overview]	Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Week 12 (MITT)
NCT01942668 (210) [back to overview]	Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 12 (MITT-VMS)
NCT01942668 (210) [back to overview]	Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 12 (MITT)
NCT01942668 (210) [back to overview]	Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 6 (MITT-VMS)
NCT01942668 (210) [back to overview]	Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 6 (MITT)
NCT01942668 (210) [back to overview]	Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Week 12 (MITT-VMS)
NCT01942668 (210) [back to overview]	Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Week 12 (MITT)
NCT01942668 (210) [back to overview]	Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 12 (MITT-VMS)
NCT01942668 (210) [back to overview]	Number of Subjects Without Bleeding for Consecutive Cycles
NCT01942668 (210) [back to overview]	Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 6 (MITT-VMS)
NCT01942668 (210) [back to overview]	Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 6 (MITT)
NCT01942668 (210) [back to overview]	Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Week 12 (MITT-VMS)
NCT01942668 (210) [back to overview]	Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Week 12 (MITT)
NCT01942668 (210) [back to overview]	Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 12 (MITT-VMS)
NCT01942668 (210) [back to overview]	Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 12 (MITT)
NCT01942668 (210) [back to overview]	Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 6 (MITT-VMS)
NCT01942668 (210) [back to overview]	Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 6 (MITT)
NCT01942668 (210) [back to overview]	Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Week 12 (MITT-VMS)
NCT01942668 (210) [back to overview]	Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Week 12 (MITT)
NCT01942668 (210) [back to overview]	Number of Days With Bleeding - Trimester 1 (Safety Pop.)
NCT01942668 (210) [back to overview]	Number of Days With Bleeding - Trimester 2 (Safety Pop.)
NCT01942668 (210) [back to overview]	Number of Days With Bleeding - Trimester 3 (Safety Pop.)
NCT01942668 (210) [back to overview]	Number of Days With Bleeding - Trimester 4 (Safety Pop.)
NCT01942668 (210) [back to overview]	Number of Days With Spotting - Trimester 1 (Safety Pop.)
NCT01942668 (210) [back to overview]	Number of Days With Spotting - Trimester 2 (Safety Pop.)
NCT01942668 (210) [back to overview]	Number of Days With Spotting - Trimester 3 (Safety Pop.)
NCT01942668 (210) [back to overview]	Number of Days With Spotting - Trimester 4 (Safety Pop.)
NCT01942668 (210) [back to overview]	Number of Subjects With Cumulative Amenorrhea From Cycle 1 to 13
NCT01942668 (210) [back to overview]	Number of Subjects With Cumulative Amenorrhea From Cycle 10 to 13
NCT01942668 (210) [back to overview]	Number of Subjects With Cumulative Amenorrhea From Cycle 11 to 13
NCT01942668 (210) [back to overview]	Number of Subjects With Cumulative Amenorrhea From Cycle 12 to 13
NCT01942668 (210) [back to overview]	Number of Subjects With Cumulative Amenorrhea From Cycle 2 to 13
NCT01942668 (210) [back to overview]	Number of Subjects With Cumulative Amenorrhea From Cycle 3 to 13
NCT01942668 (210) [back to overview]	Number of Subjects With Cumulative Amenorrhea From Cycle 4 to 13
NCT01942668 (210) [back to overview]	Number of Subjects With Cumulative Amenorrhea From Cycle 5 to 13
NCT01942668 (210) [back to overview]	Number of Subjects With Cumulative Amenorrhea From Cycle 6 to 13
NCT01942668 (210) [back to overview]	Number of Subjects With Cumulative Amenorrhea From Cycle 7 to 13
NCT01942668 (210) [back to overview]	Number of Subjects With Cumulative Amenorrhea From Cycle 8 to 13
NCT01942668 (210) [back to overview]	Number of Subjects With Cumulative Amenorrhea From Cycle 9 to 13
NCT01942668 (210) [back to overview]	Number of Subjects With Cumulative Amenorrhea From the 13th Cycle
NCT01942668 (210) [back to overview]	Number of Subjects Without Bleeding for Consecutive Cycles
NCT01942668 (210) [back to overview]	Number of Subjects Without Bleeding for Consecutive Cycles
NCT01942668 (210) [back to overview]	Number of Subjects Without Bleeding for Consecutive Cycles
NCT01942668 (210) [back to overview]	Number of Subjects Without Bleeding for Consecutive Cycles
NCT01942668 (210) [back to overview]	Number of Subjects Without Bleeding for Consecutive Cycles
NCT01942668 (210) [back to overview]	Number of Subjects Without Bleeding for Consecutive Cycles
NCT01942668 (210) [back to overview]	Number of Subjects Without Bleeding for Consecutive Cycles
NCT01942668 (210) [back to overview]	Number of Subjects Without Bleeding for Consecutive Cycles
NCT01942668 (210) [back to overview]	Number of Subjects Without Bleeding for Consecutive Cycles
NCT01942668 (210) [back to overview]	Number of Subjects Without Bleeding for Consecutive Cycles
NCT01942668 (210) [back to overview]	Number of Subjects Without Bleeding for Consecutive Cycles
NCT01942668 (210) [back to overview]	Number of Subjects Without Bleeding for Consecutive Cycles
NCT01942668 (210) [back to overview]	Primary Safety Endpoint: Endometrial Protection - Hyperplasia
NCT01942668 (210) [back to overview]	Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 1 (MITT-VMS)
NCT01942668 (210) [back to overview]	Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 10 (MITT-VMS)
NCT01942668 (210) [back to overview]	Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 11 (MITT-VMS)
NCT01942668 (210) [back to overview]	Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 12 (MITT-VMS)
NCT01942668 (210) [back to overview]	Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 2 (MITT-VMS)
NCT01942668 (210) [back to overview]	Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 3 (MITT-VMS)
NCT01942668 (210) [back to overview]	Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 4 (MITT-VMS)
NCT01942668 (210) [back to overview]	Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 5 (MITT-VMS)
NCT01942668 (210) [back to overview]	Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 6 (MITT-VMS)
NCT01942668 (210) [back to overview]	Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 7 (MITT-VMS)
NCT01942668 (210) [back to overview]	Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 8 (MITT-VMS)
NCT01942668 (210) [back to overview]	Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 9 (MITT-VMS)
NCT01942668 (210) [back to overview]	Severity of Moderate to Severe Vasomotor Symptoms - Week 1 (MITT-VMS)
NCT01942668 (210) [back to overview]	Severity of Moderate to Severe Vasomotor Symptoms - Week 10 (MITT-VMS)
NCT01942668 (210) [back to overview]	Severity of Moderate to Severe Vasomotor Symptoms - Week 11 (MITT-VMS)
NCT01942668 (210) [back to overview]	Severity of Moderate to Severe Vasomotor Symptoms - Week 12 (MITT-VMS)
NCT01942668 (210) [back to overview]	Severity of Moderate to Severe Vasomotor Symptoms - Week 2 (MITT-VMS)
NCT01942668 (210) [back to overview]	Severity of Moderate to Severe Vasomotor Symptoms - Week 3 (MITT-VMS)
NCT01942668 (210) [back to overview]	Severity of Moderate to Severe Vasomotor Symptoms - Week 4 (MITT-VMS)
NCT01942668 (210) [back to overview]	Severity of Moderate to Severe Vasomotor Symptoms - Week 5 (MITT-VMS)
NCT01942668 (210) [back to overview]	Severity of Moderate to Severe Vasomotor Symptoms - Week 6 (MITT-VMS)
NCT01942668 (210) [back to overview]	Severity of Moderate to Severe Vasomotor Symptoms - Week 7 (MITT-VMS)
NCT01942668 (210) [back to overview]	Severity of Moderate to Severe Vasomotor Symptoms - Week 8 (MITT-VMS)
NCT01942668 (210) [back to overview]	Severity of Moderate to Severe Vasomotor Symptoms - Week 9 (MITT-VMS)
NCT01942668 (210) [back to overview]	Subject Incidence With Bleeding - Trimester 1 (Safety Pop.)
NCT01942668 (210) [back to overview]	Subject Incidence With Bleeding - Trimester 2 (Safety Pop.)
NCT01942668 (210) [back to overview]	Subject Incidence With Bleeding - Trimester 3 (Safety Pop.)
NCT01942668 (210) [back to overview]	Subject Incidence With Bleeding - Trimester 4 (Safety Pop.)
NCT01942668 (210) [back to overview]	Subject Incidence With Spotting - Trimester 1 (Safety Pop.)
NCT01942668 (210) [back to overview]	Subject Incidence With Spotting - Trimester 2 (Safety Pop.)
NCT01942668 (210) [back to overview]	Subject Incidence With Spotting - Trimester 3 (Safety Pop.)
NCT01942668 (210) [back to overview]	Subject Incidence With Spotting - Trimester 4 (Safety Pop.)
NCT01942668 (210) [back to overview]	Clinical Global Impression (CGI) - Week 12 (MITT-VMS)
NCT01942668 (210) [back to overview]	Clinical Global Impression (CGI) - Week 4 (MITT-VMS)
NCT01942668 (210) [back to overview]	Clinical Global Impression (CGI) - Week 8 (MITT-VMS)
NCT01942668 (210) [back to overview]	Mean Change in Frequency of Moderate to Severe VMS for the Respective CGI Category - Week 12 (MITT-VMS)
NCT01942668 (210) [back to overview]	Mean Change in Frequency of Moderate to Severe VMS for the Respective CGI Category - Week 4 (MITT-VMS)
NCT01942668 (210) [back to overview]	Mean Change in Frequency of Moderate to Severe VMS for the Respective CGI Category - Week 8 (MITT-VMS)
NCT01942668 (210) [back to overview]	Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 1 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 10 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 11 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 12 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 2 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 3 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 4 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 5 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 6 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 7 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 8 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 9 - (MITT-VMS)
NCT01942668 (210) [back to overview]	Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 1 (MITT-VMS)
NCT01942668 (210) [back to overview]	Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 10 (MITT-VMS)
NCT01942668 (210) [back to overview]	Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 11 (MITT-VMS)
NCT01942668 (210) [back to overview]	Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 12 (MITT-VMS)
NCT01942668 (210) [back to overview]	Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 2 (MITT-VMS)
NCT01942668 (210) [back to overview]	Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 3 (MITT-VMS)
NCT01942668 (210) [back to overview]	Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 4 (MITT-VMS)
NCT01942668 (210) [back to overview]	Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 5 (MITT-VMS)
NCT01942668 (210) [back to overview]	Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 6 (MITT-VMS)
NCT01942668 (210) [back to overview]	Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 7 (MITT-VMS)
NCT01942668 (210) [back to overview]	Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 8 (MITT-VMS)
NCT01942668 (210) [back to overview]	Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 9 (MITT-VMS)
NCT01942668 (210) [back to overview]	Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 12 (MITT)
NCT01942668 (210) [back to overview]	Co-Primary Efficacy Endpoint: Frequency of Moderate to Severe Vasomotor Symptoms (MITT-VMS)
NCT01942668 (210) [back to overview]	Co-Primary Efficacy Endpoint: Frequency of Moderate to Severe Vasomotor Symptoms (MITT-VMS)
NCT01942668 (210) [back to overview]	Co-Primary Efficacy Endpoint: Severity of Moderate to Severe Vasomotor Symptoms (MITT-VMS)
NCT01942668 (210) [back to overview]	Co-Primary Efficacy Endpoint: Severity of Moderate to Severe Vasomotor Symptoms (MITT-VMS)
NCT01942668 (210) [back to overview]	Endometrial Protection - Hyperplasia
NCT01942668 (210) [back to overview]	Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 1 (MITT-VMS)
NCT01942668 (210) [back to overview]	Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 10 (MITT-VMS)
NCT01942668 (210) [back to overview]	Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 11 (MITT-VMS)
NCT01942668 (210) [back to overview]	Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 12 (MITT-VMS)
NCT02255175 (9) [back to overview]	Putamen Signal Intensity in Response to Reward During the MID fMRI Task at Pre-treatment
NCT02255175 (9) [back to overview]	Response Latency to Reward During the MID fMRI Task Following Estradiol Treatment
NCT02255175 (9) [back to overview]	Response Latency to Reward During the MID fMRI Task at Pre-treatment
NCT02255175 (9) [back to overview]	Putamen Signal Intensity in Response to Reward During the MID fMRI Task Following Estradiol Treatment.
NCT02255175 (9) [back to overview]	Caudate Signal Intensity in Response to Reward During the MID fMRI Task at Pre-treatment
NCT02255175 (9) [back to overview]	Nucleus Accumbens (NAcc) Signal Intensity in Response to Reward During the MID fMRI Task Following Estradiol Treatment.
NCT02255175 (9) [back to overview]	Nucleus Accumbens (NAcc) Signal Intensity in Response to Reward During the MID fMRI Task at Pre-treatment
NCT02255175 (9) [back to overview]	Change in Inventory of Depression and Anxiety Symptoms (IDAS) Dysphoria Scores
NCT02255175 (9) [back to overview]	Caudate Signal Intensity in Response to Reward During the MID fMRI Task Following Estradiol Treatment.
NCT02349386 (12) [back to overview]	Sex Hormone Binding Globulin (SHBG)
NCT02349386 (12) [back to overview]	Number of Patients Reporting Thromboembolic Adverse Events
NCT02349386 (12) [back to overview]	Maintenance of Testosterone Suppression at Week 24
NCT02349386 (12) [back to overview]	Maintenance of Testosterone Suppression at Week 12
NCT02349386 (12) [back to overview]	Prostate Specific Antigen (PSA)
NCT02349386 (12) [back to overview]	Maintenance of Testosterone Suppression at Week 52/ End of Study
NCT02349386 (12) [back to overview]	Follicle-stimulating Hormone (FSH)
NCT02349386 (12) [back to overview]	Follicle-stimulating Hormone (FSH)
NCT02349386 (12) [back to overview]	Luteinizing Hormone (LH)
NCT02349386 (12) [back to overview]	Luteinizing Hormone (LH)
NCT02349386 (12) [back to overview]	Prostate Specific Antigen (PSA)
NCT02349386 (12) [back to overview]	Sex Hormone Binding Globulin (SHBG)
NCT02352090 (11) [back to overview]	Anti Mullerian Hormone (AMH)
NCT02352090 (11) [back to overview]	D-dimer
NCT02352090 (11) [back to overview]	F1+2
NCT02352090 (11) [back to overview]	Fasting Insulin
NCT02352090 (11) [back to overview]	High-sensitivity C Reactive Protein
NCT02352090 (11) [back to overview]	Low-Density Lipoprotein (LDL)
NCT02352090 (11) [back to overview]	Thrombin Generation, ETP Endogenous Thrombin Potential
NCT02352090 (11) [back to overview]	High-Density Lipoprotein (HDL)
NCT02352090 (11) [back to overview]	Triglyceride
NCT02352090 (11) [back to overview]	Total Cholesterol
NCT02352090 (11) [back to overview]	Matsuda Index- Whole Body Insulin Sensitivity Index
NCT02449902 (10) [back to overview]	Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Intermediate Cells)
NCT02449902 (10) [back to overview]	Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Parabasal Cells)
NCT02449902 (10) [back to overview]	Analysis of Change From Baseline to Day 15 in Severity of the Most Bothersome Vulvar and Vaginal Atrophy (VVA) Symptom
NCT02449902 (10) [back to overview]	Analysis of Change From Baseline to Day 15 in Vaginal pH
NCT02449902 (10) [back to overview]	Analysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Color)
NCT02449902 (10) [back to overview]	Analysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Epithelial Integrity)
NCT02449902 (10) [back to overview]	Analysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Secretions)
NCT02449902 (10) [back to overview]	Analysis of Change From Baseline to Day 15 in Vaginal Bleeding Associated With Sexual Activity
NCT02449902 (10) [back to overview]	Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Superficial Cells)
NCT02449902 (10) [back to overview]	Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Epithelial Surface Thickness)
NCT02616146 (5) [back to overview]	Number of Participants With Absence of Withdrawal Bleeding (AWB), by Cycle
NCT02616146 (5) [back to overview]	Number of Participants With Breakthrough Bleeding/Spotting (BTB-S), by Cycle
NCT02616146 (5) [back to overview]	Number of Participants Who Experienced an Adverse Event (AE)
NCT02616146 (5) [back to overview]	Number of Participants Who Discontinued Treatment Due to an AE
NCT02616146 (5) [back to overview]	Number of In-Treatment Pregnancies Per 100 Woman-Years of Exposure in Participants 18-35 Years of Age (Pearl Index)
NCT02654054 (7) [back to overview]	Change From Baseline in MBL Volume to the Final Month
NCT02654054 (7) [back to overview]	Percentage of Participants With Baseline Hemoglobin <= 10.5 g/dL Who Have an Increase in Hemoglobin > 2 g/dL at Month 6
NCT02654054 (7) [back to overview]	Percentage of Participants Meeting the Criteria for Responder
NCT02654054 (7) [back to overview]	Percentage of Participants With Suppression of Bleeding at the Final Month
NCT02654054 (7) [back to overview]	Change From Baseline in MBL Volume to Month 1
NCT02654054 (7) [back to overview]	Change From Baseline in MBL Volume to Month 3
NCT02654054 (7) [back to overview]	Change From Baseline in MBL Volume to Month 6
NCT02668783 (2) [back to overview]	Number of Participants Who Discontinued Treatment Due to an AE
NCT02668783 (2) [back to overview]	Number of Participants Who Experienced an Adverse Event (AE)
NCT02691494 (7) [back to overview]	Change From Baseline in MBL Volume to the Final Month
NCT02691494 (7) [back to overview]	Change From Baseline in MBL Volume to Month 6
NCT02691494 (7) [back to overview]	Change From Baseline in MBL Volume to Month 3
NCT02691494 (7) [back to overview]	Change From Baseline in MBL Volume to Month 1
NCT02691494 (7) [back to overview]	Percentage of Participants With Suppression of Bleeding at the Final Month
NCT02691494 (7) [back to overview]	Percentage of Participants Meeting the Criteria for Responder
NCT02691494 (7) [back to overview]	Percentage of Participants With Baseline Hemoglobin <= 10.5 g/dL Who Have an Increase in Hemoglobin > 2 g/dL at Month 6
NCT02770365 (2) [back to overview]	Percentage of Subjects Identified as Responders
NCT02770365 (2) [back to overview]	Most Bothersome Symptom
NCT03049735 (44) [back to overview]	Number Of Participants With A ≥ 30% Reduction in NRS Score From Baseline to Last 35 Days of Treatment Who Had Maximum Pain Scores ≥ 4 At Baseline
NCT03049735 (44) [back to overview]	Number Of Participants Who Achieved A Maximum NRS Score ≤ 1 For Uterine Fibroid-associated Pain Over The Last 35 Days Of Treatment Who Had Maximum Pain Scores ≥ 4 During The 35 Days Prior To Randomization
NCT03049735 (44) [back to overview]	Change From Baseline In UFS-QoL Score By Health-Related Quality Of Life Total Score
NCT03049735 (44) [back to overview]	Change From Baseline In UFS-QoL Bleeding And Pelvic Discomfort Scale Score
NCT03049735 (44) [back to overview]	Change From Baseline In Progesterone Serum Concentration At Week 24
NCT03049735 (44) [back to overview]	Change From Baseline In Luteinizing Serum Concentration At Week 24
NCT03049735 (44) [back to overview]	Change From Baseline In Follicle Stimulating Serum Concentration At Week 24
NCT03049735 (44) [back to overview]	Change From Baseline In E2 Serum Concentration At Week 24
NCT03049735 (44) [back to overview]	Change From Baseline At Week 24 In UFS-QoL Bleeding And Pelvic Discomfort Scale Score As Measured By The UFS-QoL (Q1, Q2, Q5)
NCT03049735 (44) [back to overview]	Change From Baseline At Week 24 In The UFS-QoL Revised Activities Scale Score
NCT03049735 (44) [back to overview]	Change From Baseline At Week 24 In The UFS-QoL Activities Scale Score
NCT03049735 (44) [back to overview]	Change From Baseline At Week 24 In The Menorrhagia Impact Questionnaire Score For Physical Activities
NCT03049735 (44) [back to overview]	Change From Baseline At Week 24 In The Interference Of Uterine Fibroids With Social Activities Based On UFS-QoL Question 20
NCT03049735 (44) [back to overview]	Change From Baseline At Week 24 In The Interference Of Uterine Fibroids With Physical Activities Based On UFS-QoL Question 11
NCT03049735 (44) [back to overview]	Change From Baseline At Week 24 In Symptoms Assessed Using The Patient Global Assessment (PGA) Questionnaire
NCT03049735 (44) [back to overview]	Change From Baseline At Week 24 In Predose Concentrations Of Estradiol In The Relugolix Plus E2/NETA Group
NCT03049735 (44) [back to overview]	Change From Baseline At Week 24 In Function Assessed Using The PGA Questionnaire
NCT03049735 (44) [back to overview]	Change From Baseline At Week 24 In Embarrassment Caused By Uterine Fibroids Based On UFS-QoL Question 29
NCT03049735 (44) [back to overview]	Change From Baseline At Week 24 In The Menorrhagia Impact Questionnaire Score For Social Activities
NCT03049735 (44) [back to overview]	Change From Baseline At Week 24 In The UFS-QoL Symptom Severity Scale Score
NCT03049735 (44) [back to overview]	Percent Change From Baseline In Hemoglobin For Women With a Hemoglobin ≤ 10.5 g/dL At Baseline
NCT03049735 (44) [back to overview]	Percent Change From Baseline At Week 24 In Uterine Volume
NCT03049735 (44) [back to overview]	Time To MBL Response
NCT03049735 (44) [back to overview]	Time To Achieving Sustained Amenorrhea (No Or Negligible Bleeding)
NCT03049735 (44) [back to overview]	Time To Achieving Amenorrhea (No Or Negligible Bleeding)
NCT03049735 (44) [back to overview]	Sustained Amenorrhea Rate (No Or Negligible Bleeding)
NCT03049735 (44) [back to overview]	Predose Trough Concentrations Of E2 In The Relugolix Plus E2/NETA Group At Week 24
NCT03049735 (44) [back to overview]	Percentage Of Participants Experiencing Vasomotor Symptoms Through Week 12
NCT03049735 (44) [back to overview]	Percentage Of Participants With Amenorrhea Over The Last 35 Days Of Treatment
NCT03049735 (44) [back to overview]	Percentage Of Participants With A Maximum NRS Score ≤ 1 For Uterine Fibroid-Associated Pain Over The Last 35 Days Of Treatment
NCT03049735 (44) [back to overview]	Percentage Of Participants With A Hemoglobin Level ≤ 10.5 g/dL At Baseline Who Achieved An Increase Of > 2 g/dL From Baseline At Week 24
NCT03049735 (44) [back to overview]	Percentage Of Participants Who Achieved A Menstrual Blood Loss (MBL) Volume Of < 80 mL And A ≥ 50% Reduction From Baseline MBL Volume With Relugolix Plus E2/NETA
NCT03049735 (44) [back to overview]	Percentage Of Participants Experiencing Vasomotor Symptoms Through Week 24
NCT03049735 (44) [back to overview]	Percent Change From Baseline At Week 24 In Primary Uterine Fibroid Volume
NCT03049735 (44) [back to overview]	Percent Change From Baseline At Week 24 In MBL Volume
NCT03049735 (44) [back to overview]	Participants Achieving Improvement From Baseline In The PGA Questionnaire For Uterine Fibroid-related Function From Baseline At Week 24
NCT03049735 (44) [back to overview]	Participants Achieving Improvement From Baseline In The PGA Questionnaire For Symptoms From Baseline At Week 24
NCT03049735 (44) [back to overview]	Percent Change From Baseline At Week 24 In Bone Mineral Density At The Lumbar Spine (L1 To L4), Total Hip, And Femoral Neck
NCT03049735 (44) [back to overview]	Predose Trough Concentrations Of Relugolix And Norethindrone (NET) In The Relugolix Plus E2/NETA Group At Week 24
NCT03049735 (44) [back to overview]	Percent Change From Baseline At Week 12 In Bone Mineral Density At The Lumbar Spine (L1 To L4), As Assessed By DXA
NCT03049735 (44) [back to overview]	Number Of Responders With At Least 20 Points Increase From Baseline At Week 24 In UFS-QoL Revised Activities Scale Score
NCT03049735 (44) [back to overview]	Number Of Responders With At Least 20 Points Decrease In UFS-QoL Bleeding And Pelvic Discomfort Scale Score
NCT03049735 (44) [back to overview]	Number Of Participants With Hemoglobin Increase Of ≥ 1 g/dL From Baseline To Week 24 Among Those With Below Lower Limit Of Normal
NCT03049735 (44) [back to overview]	Number Of Participants With Hemoglobin ≤ 10.5 g/dL At Baseline And Achieved An Increase Of > 2 g/dL At Week 24
NCT03103087 (44) [back to overview]	Percent Change From Baseline At Week 24 In Hemoglobin For Women With A Hemoglobin Concentration ≤ 10.5 g/dL At Baseline
NCT03103087 (44) [back to overview]	Percent Change From Baseline At Week 12 In Bone Mineral Density At The Lumbar Spine (L1 to L4) As Assessed By DXA
NCT03103087 (44) [back to overview]	Number Of Responders With At Least 20 Points Increase From Baseline At Week 24 In UFS-QoL Revised Activities Scale Score
NCT03103087 (44) [back to overview]	Number Of Responders With At Least 20 Points Decrease in UFS-QoL Bleeding And Pelvic Discomfort Scale Score
NCT03103087 (44) [back to overview]	Number Of Participants With Hemoglobin Increase Of ≥ 1 g/dL From Baseline To Week 24 Among Those With Below Lower Limit Of Normal
NCT03103087 (44) [back to overview]	Number Of Participants With Hemoglobin ≤ 10.5 g/dL At Baseline And Achieved An Increase Of > 2 g/dL At Week 24
NCT03103087 (44) [back to overview]	Number Of Participants With A ≥ 30% Reduction in NRS Score From Baseline to Last 35 Days of Treatment Who Had Maximum Pain Scores ≥ 4 At Baseline
NCT03103087 (44) [back to overview]	Number Of Participants Who Achieved A Maximum NRS Score ≤ 1 For Uterine Fibroid-associated Pain Over The Last 35 Days Of Treatment Who Had Maximum Pain Scores ≥ 4 During The 35 Days Prior To Randomization
NCT03103087 (44) [back to overview]	Change From Baseline In UFS-QoL Score by Health-Related Quality of Life Total Score
NCT03103087 (44) [back to overview]	Change From Baseline in UFS-QoL Bleeding and Pelvic Discomfort Scale Score
NCT03103087 (44) [back to overview]	Change From Baseline In Progesterone Serum Concentration At Week 24
NCT03103087 (44) [back to overview]	Change From Baseline In Luteinizing Serum Concentration At Week 24
NCT03103087 (44) [back to overview]	Change From Baseline In Follicle Stimulating Serum Concentration At Week 24
NCT03103087 (44) [back to overview]	Change From Baseline In E2 Serum Concentration At Week 24
NCT03103087 (44) [back to overview]	Change From Baseline At Week 24 In UFS-QoL Bleeding And Pelvic Discomfort Scale Score As Measured By The UFS-QoL (Q1, Q2, Q5)
NCT03103087 (44) [back to overview]	Change From Baseline At Week 24 In The UFS-QoL Symptom Severity Scale Score
NCT03103087 (44) [back to overview]	Change From Baseline At Week 24 In The UFS-QoL Revised Activities Scale Score
NCT03103087 (44) [back to overview]	Percent Change From Baseline At Week 24 In Uterine Volume
NCT03103087 (44) [back to overview]	Change From Baseline At Week 24 In The Menorrhagia Impact Questionnaire Score For Social Activities
NCT03103087 (44) [back to overview]	Change From Baseline At Week 24 In The Menorrhagia Impact Questionnaire Score For Physical Activities
NCT03103087 (44) [back to overview]	Change From Baseline At Week 24 In The Interference Of Uterine Fibroids With Social Activities Based On UFS-QoL Question 20
NCT03103087 (44) [back to overview]	Change From Baseline At Week 24 In The Interference Of Uterine Fibroids With Physical Activities Based On UFS-QoL Question 11
NCT03103087 (44) [back to overview]	Change From Baseline At Week 24 In Symptoms Assessed Using The Patient Global Assessment (PGA) Questionnaire
NCT03103087 (44) [back to overview]	Change From Baseline At Week 24 In Predose Concentrations Of E2 In The Relugolix Plus E2/NETA Group
NCT03103087 (44) [back to overview]	Change From Baseline At Week 24 In Function Assessed Using The PGA Questionnaire
NCT03103087 (44) [back to overview]	Change From Baseline At Week 24 In Embarrassment Caused By Uterine Fibroids Based On UFS-QoL Question 29
NCT03103087 (44) [back to overview]	Percent Change From Baseline At Week 24 In Primary Uterine Fibroid Volume
NCT03103087 (44) [back to overview]	Percent Change From Baseline At Week 24 In MBL Volume
NCT03103087 (44) [back to overview]	Change From Baseline At Week 24 In The UFS-QoL Activities Scale Score
NCT03103087 (44) [back to overview]	Percent Change From Baseline At Week 24 In Bone Mineral Density At The Lumbar Spine (L1 To L4), Total Hip, And Femoral Neck As Assessed By DXA
NCT03103087 (44) [back to overview]	Predose Trough Concentrations Of Relugolix And NET In The Relugolix Plus E2/NETA Group At Week 24
NCT03103087 (44) [back to overview]	Participants Achieving Improvement From Baseline In PGA Questionnaire For Symptoms From Baseline At Week 24
NCT03103087 (44) [back to overview]	Participants Achieving Improvement From Baseline In PGA For Uterine Fibroid-related Function From Baseline At Week 24
NCT03103087 (44) [back to overview]	Time To MBL Response
NCT03103087 (44) [back to overview]	Time To Achieving Sustained Amenorrhea (No Or Negligible Bleeding)
NCT03103087 (44) [back to overview]	Time To Achieving Amenorrhea (No Or Negligible Bleeding)
NCT03103087 (44) [back to overview]	Sustained Amenorrhea Rate (No Or Negligible Bleeding)
NCT03103087 (44) [back to overview]	Predose Trough Concentrations Of E2 In The Relugolix Plus E2/NETA Group At Week 24
NCT03103087 (44) [back to overview]	Percentage Of Participants With Amenorrhea Over The Last 35 Days Of Treatment
NCT03103087 (44) [back to overview]	Percentage Of Participants With A Maximum Numerical Rating Scale (NRS) Score ≤ 1 For Uterine Fibroid-Associated Pain Over The Last 35 Days Of Treatment
NCT03103087 (44) [back to overview]	Percentage Of Participants With A Hemoglobin Level ≤ 10.5 g/dL At Baseline Who Achieved An Increase Of > 2 g/dL From Baseline At Week 24
NCT03103087 (44) [back to overview]	Percentage Of Participants Who Achieved A Menstrual Blood Loss (MBL) Volume Of < 80 mL And A ≥ 50% Reduction From Baseline MBL Volume With Relugolix Plus E2/NETA
NCT03103087 (44) [back to overview]	Percentage Of Participants Experiencing Vasomotor Symptoms Through Week 24
NCT03103087 (44) [back to overview]	Percentage Of Participants Experiencing Vasomotor Symptoms Through Week 12
NCT03240081 (2) [back to overview]	Change in Median Pain Scores for Intercourse After 12 Weeks Using Study Drug
NCT03240081 (2) [back to overview]	Change in Median Dyspareunia Pain Scores After 4 Weeks Using Study Drug
NCT03294538 (4) [back to overview]	Number of Participants Identified as a Responder After Completing Study Treatment in the Generic Estradiol Vaginal Cream, Estrace Vaginal Cream, and Vehicle Vaginal Cream Groups
NCT03294538 (4) [back to overview]	Number of Participants Identified as a Responder After Completing Study Treatment in the Generic Estradiol Vaginal Cream and Estrace Vaginal Cream Groups
NCT03294538 (4) [back to overview]	Number of Participants Identified as Treatment Success After Completing Study Treatment in the Generic Estradiol Vaginal Cream, Estrace Vaginal Cream, and Vehicle Vaginal Cream Groups
NCT03294538 (4) [back to overview]	Number of Participants Identified as Treatment Success After Completing Study Treatment in the Generic Estradiol Vaginal Cream and Estrace Vaginal Cream Groups
NCT04865029 (8) [back to overview]	Number of Participants With Scores 1 or 2 on the 9-point World Health Organization (WHO) Ordinal Scale at Discharge, Measured up to Day 21
NCT04865029 (8) [back to overview]	Number of Participants With Each Cause of Death
NCT04865029 (8) [back to overview]	Serious Adverse Events Occurrence
NCT04865029 (8) [back to overview]	Number of Days Death Occurred After Admission
NCT04865029 (8) [back to overview]	Readmission
NCT04865029 (8) [back to overview]	Grade 3 Adverse Events Occurrence
NCT04865029 (8) [back to overview]	Length of Hospital Stay
NCT04865029 (8) [back to overview]	Number of Patients Requiring Invasive Mechanical Ventilation

[back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top]